CHANNEL THERAPEUTICS CORP (CHRO) Stock Overview
USA - NYSEARCA:CHRO - US1711261057 - Common Stock
CHRO Key Statistics, Chart & Performance
The current stock price of CHRO is 1.35 USD. In the past month the price increased by 32.35%. In the past year, price increased by 9.76%.
CHRO Latest News, Press Relases and Analysis
CHRO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.53 | 402.76B | ||
| AMGN | AMGEN INC | 13.38 | 157.07B | ||
| GILD | GILEAD SCIENCES INC | 15.63 | 150.06B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.88 | 108.04B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.66 | 61.26B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 60.75B | ||
| ARGX | ARGENX SE - ADR | 88.74 | 50.32B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.02 | 34.14B | ||
| INSM | INSMED INC | N/A | 33.75B | ||
| NTRA | NATERA INC | N/A | 26.42B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.40B | ||
| BIIB | BIOGEN INC | 9.36 | 21.98B |
Related stock screener links
About CHRO
Company Profile
Chromocell Therapeutics Corp. is a clinical-stage biotech company that engages in the development and commercialization of new therapeutics to alleviate pain. The company is headquartered in North Brunswick, New Jersey and currently employs 4 full-time employees. The firm's clinical focus is to selectively target the sodium ion-channel, NaV1.7, as well as other receptors in the NaV family. Its lead compound, CC8464, is designed to address both the underlying condition and mitigate the burning pain symptoms, which erythromelalgia (EM) patients experience by blocking the NaV1.7 sodium channel. CC8464 has completed Phase I study. A total of approximately 207 healthy subjects have been dosed in four Phase I studies (CC8464-1001, CC8464-1002, CC8464-1003, and 1807-CL-0102) with study treatment.
Company Info
CHANNEL THERAPEUTICS CORP
685 US Highway One
North Brunswick NEW JERSEY US
Employees: 4
Phone: 19176446313
CHANNEL THERAPEUTICS CORP / CHRO FAQ
Can you describe the business of CHANNEL THERAPEUTICS CORP?
Chromocell Therapeutics Corp. is a clinical-stage biotech company that engages in the development and commercialization of new therapeutics to alleviate pain. The company is headquartered in North Brunswick, New Jersey and currently employs 4 full-time employees. The firm's clinical focus is to selectively target the sodium ion-channel, NaV1.7, as well as other receptors in the NaV family. Its lead compound, CC8464, is designed to address both the underlying condition and mitigate the burning pain symptoms, which erythromelalgia (EM) patients experience by blocking the NaV1.7 sodium channel. CC8464 has completed Phase I study. A total of approximately 207 healthy subjects have been dosed in four Phase I studies (CC8464-1001, CC8464-1002, CC8464-1003, and 1807-CL-0102) with study treatment.
Can you provide the latest stock price for CHANNEL THERAPEUTICS CORP?
The current stock price of CHRO is 1.35 USD. The price increased by 7.14% in the last trading session.
Does CHRO stock pay dividends?
CHRO does not pay a dividend.
What is the ChartMill technical and fundamental rating of CHRO stock?
CHRO has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Can you provide the PE ratio for CHRO stock?
CHANNEL THERAPEUTICS CORP (CHRO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.28).
What is the ownership structure of CHANNEL THERAPEUTICS CORP (CHRO)?
You can find the ownership structure of CHANNEL THERAPEUTICS CORP (CHRO) on the Ownership tab.
CHRO Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to CHRO. When comparing the yearly performance of all stocks, CHRO turns out to be only a medium performer in the overall market: it outperformed 42.86% of all stocks.
CHRO Financial Highlights
Over the last trailing twelve months CHRO reported a non-GAAP Earnings per Share(EPS) of -1.28. The EPS decreased by -197.6% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -810.01% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |